Yan Chaolong, Yan Huiying, Mao Jiannan, Liu Yutong, Xu Li, Zhao Hongting, Shen Jiaqi, Cao Yan, Gao Yongyue, Li Kuanyu, Jin Wei
Department of Neurosurgery, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China.
Department of Neurosurgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Front Neurosci. 2020 Nov 13;14:557170. doi: 10.3389/fnins.2020.557170. eCollection 2020.
NLRP3 inflammasome has been considered as an important contributor to inflammation and neuronal death after traumatic brain injury (TBI). Oridonin (Ori), the major active ingredient of Chinese herbal medicine , has been proved to be a covalent NLRP3 inhibitor with strong anti-inflammation activity. The purpose of this study was to investigate the effect of Ori on inflammation and brain injury induced by TBI. Adult male C57BL/6 mice were subjected to closed-head injury using Hall's weight-dropping method. Ori was injected directly intraperitoneally at a dose of 10 mg/kg within 30 min after TBI and injected once daily until the experiments ended. Our results showed that NLRP3 inflammasome was activated within 24 h post-TBI. The expression of NLRP3 inflammasome components (NLRP3, ASC, and caspase-1) was significantly decreased after treatment with Ori. Besides, the secretion of IL-1β and IL-18, downstream inflammatory factors of activated caspase-1, was reduced by Ori treatment. Importantly, Ori administration further protected the blood-brain barrier, alleviated brain edema, reduced cortical lesion volume, decreased cell death, and attenuated neurological deficits after TBI. Our findings indicate that NLRP3 inflammasome participated in the secondary injury after TBI and the application of Ori may provide neuroprotection via inhibiting NLRP3 inflammasome in animal models, suggesting that Ori might be a promising candidate for patients with TBI.
NLRP3炎性小体被认为是创伤性脑损伤(TBI)后炎症和神经元死亡的重要促成因素。冬凌草甲素(Ori)是中药的主要活性成分,已被证明是一种具有强大抗炎活性的共价NLRP3抑制剂。本研究的目的是探讨Ori对TBI诱导的炎症和脑损伤的影响。成年雄性C57BL/6小鼠采用Hall的重物坠落法进行闭合性颅脑损伤。在TBI后30分钟内,以10mg/kg的剂量直接腹腔注射Ori,每天注射一次,直至实验结束。我们的结果表明,NLRP3炎性小体在TBI后24小时内被激活。用Ori治疗后,NLRP3炎性小体成分(NLRP3、ASC和caspase-1)的表达显著降低。此外,Ori治疗降低了活化的caspase-1的下游炎症因子IL-1β和IL-18的分泌。重要的是,给予Ori进一步保护了血脑屏障,减轻了脑水肿,减小了皮质损伤体积,减少了细胞死亡,并减轻了TBI后的神经功能缺损。我们的研究结果表明,NLRP3炎性小体参与了TBI后的继发性损伤,在动物模型中应用Ori可能通过抑制NLRP3炎性小体提供神经保护作用,这表明Ori可能是TBI患者的一个有前景的候选药物。